Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-ketoglutarate dehydrogenase subunit 4 (KGD4) is an evolutionarily conserved structural subunit of the mitochondrial alpha-ketoglutarate dehydrogenase enzyme complex, crucial for the citric acid cycle and energy production in eukaryotic cells. KGD4 acts as a molecular adaptor that links the E1-E2 catalytic core to the E3 subunit, stabilizing the assembled complex and ensuring efficient enzymatic activity. Originally annotated as a mitochondrial ribosomal protein (MRPS36), further research has shown that KGD4 does not contribute to ribosomal function but rather plays a vital role in the organization and stability of the dehydrogenase complex. Defects in KGD4 are associated with mitochondrial diseases such as Leigh disease and may have broader implications in aging, neurodegeneration, and cancer due to its impact on cellular energy metabolism and mitochondrial function.
Not applicable (no current drugs directly target KGD4). For the alpha-ketoglutarate dehydrogenase complex: inhibition by metabolic poisons (e.g., arsenite), but these act on the enzyme complex rather than specifically on KGD4.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-ketoglutarate dehydrogenase subunit 4 (KGD4).